CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
32.98
+0.74 (2.30%)
Nov 21, 2024, 1:29 PM EST - Market open
CG Oncology Revenue
CG Oncology had revenue of $43.00K in the quarter ending September 30, 2024, with 377.78% growth. This brings the company's revenue in the last twelve months to $684.00K. In the year 2023, CG Oncology had annual revenue of $204.00K with 6.81% growth.
Revenue (ttm)
$684.00K
Revenue Growth
+6.81%
P/S Ratio
n/a
Revenue / Employee
$11,213
Employees
61
Market Cap
2.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 204.00K | 13.00K | 6.81% |
Dec 31, 2022 | 191.00K | -10.17M | -98.16% |
Dec 31, 2021 | 10.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCGON News
- 2 months ago - CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - CG Oncology: Promising Data, But Looks Expensive - Seeking Alpha
- 3 months ago - CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - CG Oncology Bringing Undervalued Innovation To Bladder Cancer - Seeking Alpha
- 6 months ago - CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC - GlobeNewsWire
- 6 months ago - CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting - GlobeNewsWire
- 7 months ago - CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value - Seeking Alpha